The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients

Antiviral Research

Volumn 102, Issue , 2014, Pages 44-53

  Bienvenu, Emile ^a   Swart, Marelize ^b   Dandara, Collet ^b   Ashton, Michael ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Efavirenz; HIV; Plasma level; Predictive value; SNP; Tuberculosis

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EFAVIRENZ; RIFAMPICIN; RITONAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; EVENING DOSAGE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RWANDA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS LOAD; YOUNG ADULT; BLOOD LEVEL; CHEMISTRY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; PLASMA; SNP; ALLELE; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FOLLOW UP; HETEROZYGOTE; HOMOZYGOTE; HUMAN TISSUE; MEDICATION COMPLIANCE; PHARMACOGENETICS;

EFAVIRENZ; HIV; PLASMA LEVEL; PREDICTIVE VALUE; SNP; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLASMA; POLYMORPHISM, SINGLE NUCLEOTIDE; RWANDA; TUBERCULOSIS; YOUNG ADULT;

EID: 84892879896     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.11.011     Document Type: Article

References (41)

1. Avihingsanon A., Hemachandraa A., van de Lugta J. Antiretroviral therapy for HIV-associated tuberculosis. Asian Biomed. 2009, 3:73-87.
2. Bélanger A.S., Caron P., Harvey M., Zimmerman P.A., Mehlotra R.K., Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 2009, 37:1793-1796.
3. Bienvenu E., Hoffmann K.J., Ashton M., Kayumba P.C. A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments. Biomed. Chromatogr. 2013, 27(11):1554-1559.
4. Bienvenu E., Swart M., Dandara C., Ekman A., Äbelö A., Wonkam A., Ashton M. Frequencies of single nucleotide polymorphisms in cytochrome P450 genes (CYP1A2, 2A6, 2B6, 3A4, and 3A5) in a Rwandan population: difference to other African populations. Curr. Pharmacogenomics Person Med. 2013, 11(3):237-246.
5. Burman W.J., Gallicano K., Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin. Infect. Dis. 1999, 28:419-429.
6. Cabrera Figueroa S., Iglesias Gómez A., Sánchez Martín A., de la Paz Valverde Merino M., Domínguez-Gil Hurlé A., Cordero Sánchez M. Long-term efficacy and safety of efavirenz dose reduction to 200mg once daily in a Caucasian patient with HIV. Clin. Drug Investig. 2010, 30:405-411.
7. Centers for Disease Control and Prevention (CDC), 2007. Managing Drug Interactions in the Treatment of HIV-related Tuberculosis, Atlanta.
8. Cohen K., Grant A., Dandara C., McIlleron H., Pemba L., Fielding K., Charalombous S., Churchyard G., Smith P., Maartens G. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir. Ther. 2009, 14:687-695.
9. di Iulio J., Fayet A., Arab-Alameddine M., Rotger M., Lubomirov R., Cavassini M., Furrer H., Günthard H.F., Colombo S., Csajka C., Eap C.B., Decosterd L.A., Telenti A. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 2009, 19:300-309.
10. Gengiah T.N., Holford N.H., Botha J.H., Gray A.L., Naidoo K., Abdool Karim S.S. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur. J. Clin. Pharmacol. 2012, 68:689-695.
11. Gunder L.M., Martin S.A. Essentials of Medical Genetics for Health Professionals 2011, Jones & Bartlett Learning, Sudbury, Ontario.
12. Holzinger E.R., Grady B., Ritchie M.D., Ribaudo H.J., Acosta E.P., Morse G.D., Gulick R.M., Robbins G.K., Clifford D.B., Daar E.S., McLaren P., Haas D.W. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS clinical trials group protocols implicates several CYP2B6 variants. Pharmacogenet. Genomics 2012, 22:858-867.
13. King J., Aberg J.A. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008, 22:1709-1717.
14. Kwara A., Tashima K.T., Dumond J.B., Poethke P., Kurpewski J., Kashuba A.D., Court M.H., Greenblatt D.J. Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. Antimicrob. Agents Chemother. 2011, 55:3527-3533.
15. *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br. J. Clin. Pharmacol. 2009, 67:427-436.
16. Kwara A., Lartey M., Sagoe K.W., Kenu E., Court M.H. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009, 16:2101-2106.
17. Kwara A., Lartey M., Sagoe K.W., Xexemeku F., Kenu E., Oliver-Commey J., Boima V., Sagoe A., Boamah I., Greenblatt D.J., Court M.H. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J. Clin. Pharmacol. 2008, 48:1032-1040.
18. Lewis C.M., Knight J. Introduction to genetic association studies. Cold Spring Harb. Protoc. 2012, 1:297-306.
19. Li T., Chiang J.Y. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4α and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab. Dispos. 2006, 34:756-764.
20. Luetkemeyer A.F., Rosenkranz S.L., Lu D., Marzan F., Ive P., Hogg E., Swindells S., Benson C.A., Grinsztejn B., Sanne I.M., Havlir D.V., Aweeka F. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS clinical trials group A5221 stride study. Clin. Infect. Dis. 2013, 57:586-593.
21. Manzi S.F., Shannon M. Drug interactions - a review. Clin. Pediatr. Emerg. Med. 2005, 6:93-102.
22. Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001, 15:71-75.
23. Mutlib A.E., Chen H., Nemeth G.A., Markwalder J.A., Seitz S.P., Gan L.S., Christ D.D. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab. Dispos. 1999, 27:1319-1333.
24. Ngaimisi E., Mugusi S., Minzi O.M., Sasi P., Riedel K.D., Suda A., Ueda N., Janabi M., Mugusi F., Haefeli W.E., Burhenne J., Aklillu E. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin. Pharmacol. Ther. 2011, 90:406-413.
25. Ogburn E.T., Jones D.R., Masters A.R., Xu C., Guo Y., Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 2010, 38:1218-1229.
26. Parikh R., Mathai A., Parikh S., Chandra Sekhar.G., Thomas R. Understanding and using sensitivity, specificity and predictive values. Indian J. Ophthalmol. 2008, 56:45-50.
27. Pozniak A.L., Coyne K.M., Miller R.F., Lipman M.C., Freedman A.R., Ormerod L.P., Johnson M.A., Collins S., Lucas S.B. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med. 2011, 12:517-524.
28. Ramachandran G., Hemanth Kumar A.K., Rajasekaran S., Kumar P., Ramesh K., Anitha S., Narendran G., Menon P., Gomathi C., Swaminathan S. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob. Agents Chemother. 2009, 53:863-868.
29. Rodríguez-Nóvoa S., Barreiro P., Jiménez-Nácher I., Soriano V. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics 2006, 6:234-245.
30. Sánchez A., Cabrera S., Santos D., Valverde M.P., Fuertes A., Domínguez-Gil A., García M.J. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob. Agents Chemother. 2011, 55:5314-5324.
31. Shapiro L.E., Shear N.H. Drug interactions: proteins, pumps, and P-450s. J. Am. Acad. Dermatol. 2002, 47:467-484.
32. Sukasem C., Cressey T.R., Prapaithong P., Tawon Y., Pasomsub E., Srichunrusami C., Jantararoungtong T., Lallement M., Chantratita W. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br. J. Clin. Pharmacol. 2012, 74:1005-1012.
33. Swart M., Skelton M., Ren Y., Smith P., Takuva S., Dandara C. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet. Genomics 2013, 23:415-427.
34. Szalat A., Gershkovich P., Ben-Ari A., Shaish A., Liberman Y., Boutboul E., Gotkine M., Hoffman A., Harats D., Leitersdorf E., Meiner V. Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. Biochim. Biophys. Acta 2007, 1771:839-844.
35. Uttayamakul S., Likanonsakul S., Manosuthi W., Wichukchinda N., Kalambaheti T., Nakayama E.E., Shioda T., Khusmith S. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res. Ther. 2010, 26(7):8.
36. Ward B.A., Gorski J.C., Jones D.R., Hall S.D., Flockhart D.A., Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 2003, 306:287-300.
37. Wen X., Wang J.S., Neuvonen P.J., Backman J.T. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19, and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 2002, 57:799-804.
38. World Health Organization (WHO), 2012. Global Tuberculosis Control. Report 2012, Geneva.
39. World Health Organization (WHO), 2010. Treatment of Tuberculosis: Guidelines, fourth ed., Geneva.
40. Kwara, A., Yang, H., Lartey, M., Sagoe, K., Court M., 2011. Identification of HIV-infected Ghanaian patients with low or high efavirenz plasma mid-dose concentrations, 6th IAS Conference on HIV pathogenesis and treatment: abstract no. MOPE198. In: sixth IAS Conference on HIV and Pathogenesis, Treatment and Prevention, Rome, Italy. July 17-20, 2011. <. http://www.medadvocates.org/drugs/efavirenz/conferences/conferences.htm/.
41. Court, M., Almutairi, F., Greenblatt, D., 2013. Identification of isoniazid as a potent inhibitor of CYP2A6-mediated Efavirenz 7-hydroxylation in CYP2B6*6 Genotyped Human Liver Microsomes: abstract 517. In: 20th Conference on Retrovirus and Opportunistic Infections, Atlanta, USA. March 3-6, 2013. <. http://www.medadvocates.org/drugs/efavirenz/conferences/conferences.htm/.